Allogeneic bone marrow transplantation in the treatment of XXXX .

@entity1 @entity981 @entity231 @entity5 @entity2150 @entity786 @entity3885 @entity3052 @entity1503 @entity1582 @entity2132 @entity1583 @entity1893 @entity978 @entity3230 @entity1860 @entity11807
The current use of allogeneic bone marrow transplantation in various @entity1503 is reviewed. Bone marrow transplantation (BMT) involves infusion of bone marrow from a suitable donor into a properly conditioned recipient. Most BMT is allogeneic, in which the donor is genetically dissimilar but shares some common tissue antigens with the recipient. Almost all @entity1 undergoing allogeneic BMT must be "prepared" with high-dose @entity786 to prevent graft rejection. Most @entity1 with @entity1583 also receive total body irradiation to eradicate malignant cells located in areas inaccessible to the systemic circulation. Bone marrow transplantation is the treatment of choice for severe @entity2150 . In @entity3052 , the best results are observed in young @entity1 undergoing BMT in first remission. In @entity981 , BMT is usually reserved for @entity1 in second or subsequent remission. Early results are promising in @entity1 with @entity1860 who receive BMT before the accelerated phase or blast crisis of this disease. Allogeneic BMT offers an opportunity for cure in some @entity1 with relapses of @entity978 or those with certain subtypes of @entity1893 . Other diseases for which BMT has been used include severe @entity3230 disease, @entity11807 , and @entity1582 . Complications of BMT include graft failure or rejection, acute and @entity2132 , and infectious complications; late complications, such as restrictive and @entity3885 , @entity231 , sterility, and secondary @entity5 , may also occur. Bone marrow transplantation has become an important treatment for many @entity1503 , but it will probably remain a treatment reserved for only a few highly specialized centers. If morbidity and mortality caused by transplant-related complications can be reduced, BMT may be offered to older @entity1 and those without HLA-identical sibling donors.
